CNMD Quote, Financials, Valuation and Earnings

Electromed has a net margin of 1.88% compared to Conmed's net margin of 12.06%. Conmed's return on equity of 12.88% beat Electromed's return on equity of 16.57%.

Conmed has a consensus price target of $66.60, signalling upside risk potential of 27.66%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 72.81%. Given that Electromed has higher upside potential than Conmed, analysts believe Electromed is more attractive than Conmed.

Conmed has a beta of 1.236, which suggesting that the stock is 23.611% more volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

Conmed has a quarterly dividend of $0.20 per share corresponding to a yield of 1.53%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Conmed pays 18.62% of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend. Conmed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Conmed quarterly revenues are $321.3M, which are larger than Electromed quarterly revenues of $15.7M. Conmed's net income of $6M is higher than Electromed's net income of $1.9M. Notably, Conmed's price-to-earnings ratio is 13.73x while Electromed's PE ratio is 27.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conmed is 1.23x versus 3.21x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of 1.88% compared to Conmed's net margin of -14.17%. Conmed's return on equity of 12.88% beat IRIDEX's return on equity of -218.69%.

Conmed has a consensus price target of $66.60, signalling upside risk potential of 27.66%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 127.27%. Given that IRIDEX has higher upside potential than Conmed, analysts believe IRIDEX is more attractive than Conmed.

Conmed has a beta of 1.236, which suggesting that the stock is 23.611% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.546%.

Conmed has a quarterly dividend of $0.20 per share corresponding to a yield of 1.53%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Conmed pays 18.62% of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend. Conmed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Conmed quarterly revenues are $321.3M, which are larger than IRIDEX quarterly revenues of $11.9M. Conmed's net income of $6M is higher than IRIDEX's net income of -$1.7M. Notably, Conmed's price-to-earnings ratio is 13.73x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conmed is 1.23x versus 0.30x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 1.88% compared to Conmed's net margin of -35.24%. Conmed's return on equity of 12.88% beat Myomo's return on equity of -38.11%.

Conmed has a consensus price target of $66.60, signalling upside risk potential of 27.66%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 284.96%. Given that Myomo has higher upside potential than Conmed, analysts believe Myomo is more attractive than Conmed.

Conmed has a beta of 1.236, which suggesting that the stock is 23.611% more volatile than S&P 500. In comparison Myomo has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.933%.

Conmed has a quarterly dividend of $0.20 per share corresponding to a yield of 1.53%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Conmed pays 18.62% of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend. Conmed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Conmed quarterly revenues are $321.3M, which are larger than Myomo quarterly revenues of $9.8M. Conmed's net income of $6M is higher than Myomo's net income of -$3.5M. Notably, Conmed's price-to-earnings ratio is 13.73x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conmed is 1.23x versus 2.28x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 1.88% compared to Conmed's net margin of -77.93%. Conmed's return on equity of 12.88% beat Stereotaxis's return on equity of -174.6%.

Conmed has a consensus price target of $66.60, signalling upside risk potential of 27.66%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 96.51%. Given that Stereotaxis has higher upside potential than Conmed, analysts believe Stereotaxis is more attractive than Conmed.

Conmed has a beta of 1.236, which suggesting that the stock is 23.611% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.028%.

Conmed has a quarterly dividend of $0.20 per share corresponding to a yield of 1.53%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Conmed pays 18.62% of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend. Conmed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Conmed quarterly revenues are $321.3M, which are larger than Stereotaxis quarterly revenues of $7.5M. Conmed's net income of $6M is higher than Stereotaxis's net income of -$5.8M. Notably, Conmed's price-to-earnings ratio is 13.73x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Conmed is 1.23x versus 7.18x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.